Following a competitive tender process, RayStation has been chosen as the treatment planning system for the CYCLHAD Hadrontherapy Center, located in Caen, France. The center is due to open in 2018 and will be France’s third clinical proton therapy center.
CYCLHAD will deliver proton therapy treatments via IBA’s ProteusOne compact system, with the first patient treatment scheduled to take place in June. The center is owned, operated and managed by SAS CYCLHAD, and treatment will be conducted by the medical teams of Centre François Baclesse, a comprehensive cancer center located in Caen.
A further phase of expansion is planned for the center, including the installation of the NHa C400 cyclotron system to enable research with carbon ions.
The RayStation purchase includes the modules for pencil beam scanning, adaptive therapy, biology and patient modeling.
Philippe Lagalle, CEO of SAS CYCLHAD, says: “As a pioneering center, we need partners who can deliver when it comes to advanced techniques. RaySearch is a world leader in treatment planning for proton therapy and has proven expertise in supporting IBA systems. RayStation’s power and innovative capabilities will help us to ensure world-class treatment and research. We also plan to evaluate the possibilities of the forthcoming RayCare* oncology information system.”
Johan Löf, CEO of RaySearch, says: “We are proud to support one of France’s first proton centers. Proton therapy is an important focus area for RaySearch. We have a large market share and our success in this area continues to grow. RaySearch has a strong strategic collaboration with IBA, which builds on our joint commitment to taking proton therapy to new levels.”
About the ARCHADE program
ARCHADE (Advanced Resource Centre for Hadrontherapy in Europe) is a collaborative initiative to create a European center dedicated to hadron therapy research, development and clinical treatment. The CYCLHAD Hadrontherapy Center, Located in Caen, France, will carry out multidisciplinary research and treat up to 345 patients per year using proton therapy.
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch, and which will be launched in December 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since November 2003.
To learn more about RaySearch, go to: www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00